Bristol Myers Squibb Company $BMY Holdings Lifted by Macquarie Group Ltd.

Key Points

• Macquarie Group Ltd. increased its Bristol Myers Squibb stake by 2.0% in the fourth quarter, adding 39,889 shares and bringing its total holding to about 2.0 million shares worth roughly $108.7 million.
• Bristol Myers Squibb continues to attract major institutional interest, with firms like Norges Bank, Bank of New York Mellon, and Geode Capital Management also reporting sizable positions; institutions now own 76.41% of the stock.
• Analysts are mixed on BMY, with a consensus Hold rating and average price target of $61.31, even as the company posted stronger-than-expected quarterly earnings and revenue and highlighted growth in its newer drug portfolio.

Macquarie Group Ltd. grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 2.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,016,204 shares of the biopharmaceutical company's stock after purchasing an additional 39,889 shares during the period. Macquarie Group Ltd. owned approximately 0.10% of Bristol Myers Squibb worth $108,700,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of BMY. Norges Bank bought a new position in Bristol Myers Squibb in the 4th quarter worth about $1,947,272,000. Bank of New York Mellon Corp grew its position in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock worth $1,321,308,000 after purchasing an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC grew its position in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Man Group plc grew its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Bristol Myers Squibb by 530.6% in the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company's stock valued at $245,946,000 after acquiring an additional 4,588,601 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

BMY has been the subject of several recent analyst reports. Guggenheim reiterated a "buy" rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Barclays initiated coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They issued an "overweight" rating and a $75.00 price objective for the company. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 price objective for the company. Piper Sandler reiterated an "overweight" rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, UBS Group reiterated a "buy" rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and an average target price of $61.31.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Bristol Myers Squibb Stock Up 0.3%

BMY stock opened at $57.05 on Friday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The firm has a market cap of $116.49 billion, a PE ratio of 16.02, a P/E/G ratio of 0.16 and a beta of 0.24. The firm has a 50 day simple moving average of $57.73 and a 200 day simple moving average of $56.87. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the business earned $1.80 earnings per share. The business's quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.